Physician profile
David J Lemons
NPI 1932338753
$6,779.30
in general payments reported to CMS, 2019-2025
26 companies · $2,668 in 2025
The $2,668 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $219 · 2021: $2,074 · 2022: $662 · 2023: $445 · 2024: $564 · 2025: $2,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,931 · Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,930.70 |
| Food and Beverage | $1,746.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,315.80 | 2020-2025 | Aveir, Jot Dx, Assurity |
| Medtronic, INC. | $1,412.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $419.98 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $178.36 | 2020-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $153.07 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.60 | 2022-2024 | Jardiance |
| Boston Scientific Corporation | $121.32 | 2022-2023 | Watchman Access System |
| Amgen INC. | $116.01 | 2021-2024 | Repatha |
| Medtronic Vascular, INC. | $113.09 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $99.00 | 2019-2024 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $96.96 | 2021-2023 | Farxiga |
| Angiodynamics, INC. | $84.76 | 2023 | Alphavac |
| Abiomed | $80.40 | 2024 | Impella |
| Shockwave Medical, INC | $59.02 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $56.16 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $46.58 | 2022-2023 | |
| Pfizer INC. | $45.18 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $36.30 | 2022-2024 | Xarelto |
| Acist Medical Systems, INC. | $32.62 | 2022 | |
| Novo Nordisk INC | $31.49 | 2021-2025 | Wegovy |
| Cardiovascular Systems INC. | $29.85 | 2019-2020 | |
| Scpharmaceuticals INC. | $28.87 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $28.75 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $21.04 | 2021 | |
| Chiesi USA, INC. | $14.18 | 2022 | |
| Daiichi Sankyo INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.